CanSinoBIO’s inhaled COVID booster stronger against BA.1 Omicron subvariant than Sinovac shotBusiness, R&D, TherapeuticsChinese vaccine firm CanSino Biologic’s inhalation-based candidate elicited a better antibody response as a booster against the BA.1 Omicron sub-variant than Sinovac’s shot, but the antibody level dropped in months, clinical trial data showed. Read more July 29, 2022/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2022/07/CanSinoBIO.jpg 600 901 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2022-07-29 02:05:372022-07-29 10:59:26CanSinoBIO’s inhaled COVID booster stronger against BA.1 Omicron subvariant than Sinovac shot